ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Evaluation of the hepatitis c virus screening program in the Marche Region (Italy): experience from the Pesaro-Urbino health authority.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) infection remains a global health challenge despite the availability of highly effective direct-acting antivirals. Early case identification through population screening is crucial to achieve the WHO target of HCV elimination. We conducted a population-based screening program in the Marche Region (Italy), focusing on the Local Health Authority of Pesaro-Urbino, to evaluate the feasibility and first-year outcomes of the national HCV screening campaign.
methodsBetween August 2023 and July 2024, individuals born between 1969 and 1989 residing in the Pesaro-Urbino area were invited to undergo free HCV testing. Screening was performed using serological anti-HCV antibody assays, and positive cases were further evaluated with HCV-RNA testing to confirm active infection.
resultsA total of 6,319 individuals (12.4% of the eligible population) participated in the screening program. Anti-HCV antibodies were detected in 64 participants (1.0%). Among them, 8 cases (0.13% of the total screened) showed detectable HCV-RNA, confirming ongoing infection.
conclusionsThe prevalence of active HCV infection in this population was low, consistent with declining national and European trends. However, the program successfully identified untreated viremic individuals who can now access curative therapy. Our findings highlight both the importance and the challenges of implementing large-scale screening campaigns in low-prevalence settings, emphasizing the need for tailored strategies to maximize participation rates and achieve elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.